ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM Immupharma Plc

1.15
-0.005 (-0.43%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.005 -0.43% 1.15 1.02 1.255 1.27 1.27 1.27 733,994 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -2.92M -0.0070 -1.81 4.81M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 1.16p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 2.90p.

Immupharma currently has 416,440,000 shares in issue. The market capitalisation of Immupharma is £4.81 million. Immupharma has a price to earnings ratio (PE ratio) of -1.81.

Immupharma Share Discussion Threads

Showing 39176 to 39198 of 39200 messages
Chat Pages: 1568  1567  1566  1565  1564  1563  1562  1561  1560  1559  1558  1557  Older
DateSubjectAuthorDiscuss
14/12/2024
10:28
Nice £6K buy just before cop yesterday, let's hope it was someone in the know so to speak,well we are due news soon,we may be pleasantly surprised, maybe.
bri15
29/11/2024
12:58
chesty1 - sticky bun, currant bun, Chelsea bun or hot cross bun?
lord loads of lolly
29/11/2024
11:07
Another stock for the bun
chesty1
26/11/2024
11:53
kingston - just goes to show - you can't trust what the scientists tell you!

waterloo - as I keep pointing out to Nobby, it's McCarthy's job to keep the company running, which, despite serial failures by the scientists, he's succeeded in doing. I don't like what he does, but I think it's important to recognise where the problems lie, and it really isn't with McCarthy.

Or are you of the opinion that they should have just been allowed to go under?

supernumerary
26/11/2024
11:29
Some people really shouldn't be allowed to run companies., at least public ones. Macarthy being almost top of the list. (I can think of a few others).

Serial failures.

waterloo01
26/11/2024
10:59
The company was in the money on the warrants of INC, and if exercised at that time and sold the shares in the market would have made a tidy profit. Instead, the company paid £75k to extend the time limit for those warrants exercisable at 19.5 p, but INC's shares have tanked today to 3.5 p. Those warrants are under the water, and the £75k paid is now completely sunk. What a disaster of the decision made by the CEO of IMM!

Not only that he personally holds a lot of shares in INC so he has lost money there too, at least on paper.

kingston78
26/11/2024
10:06
lol - wearing your heart on your sleeve, Nobby! It looks more like another science disaster to me. Which will have to be rescued, yet again, by another successful McCarthy fund raising :¬)
supernumerary
26/11/2024
07:03
Uh oh another McCarthy disaster!
nobbygnome
14/11/2024
17:38
Another article on the cell therapy approach. Looks increasingly as though that's the way lupus treatment will ultimately go.



BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic lupus erythematosus (SLE), providing further evidence that the emerging class of candidates can reset the immune system.

Interest in using CAR-T cell therapies has taken off since German researchers posted data on five people with SLE in 2022. An update on the study in February showed eight SLE patients remained in remission. Patients had severe, progressive disease that was resistant to standard immunomodulating treatments. The researchers also reported data in systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM).


BMS is part of a wave of drug developers, both large and small, that hustled CD19-directed CAR-T cell therapies into autoimmune trials in the aftermath of the initial SLE data drop. The Big Pharma is sharing data at ACR Convergence 2024, where it is presenting results that go beyond the existing abstract.

[ ... ]

supernumerary
07/11/2024
12:55
Nobby - I came across this by accident:

hxxps://www.theatlantic.com/health/archive/2024/11/lupus-car-t-immune-reset-autoimmune-disease/680521

I can't get access to the original article, but from other reports it looks as though teclistamab might be a very valuable drug for lupus. Can you see the original paper? If it's cheap, effective, readily available, and approved (for at least something) then it might contribute to reluctance by Avion to run this trial.

supernumerary
29/10/2024
18:36
qaz - looks like you need a new body then.
lord loads of lolly
17/10/2024
11:58
but my BODDDDYYYYYYYYYYYYYYYYY is telling me YESSSSSSSSSSS!
qazwsxedc69
17/10/2024
11:38
My gut tells me no. !
robward
17/10/2024
06:47
Are Avion ever going to start the phase II/III….
nobbygnome
17/10/2024
06:32
STX, SBTX, BT, VOD, GDR, CPI? Need any more?

It's taken longer than expected here, but it will come.

Have a great day in your bedsit.

socionomics
06/10/2024
10:19
Socionomics, most of the shares that you have recommended have turned out to be duds.
kingston78
18/9/2024
12:27
So so close now!
socionomics
17/9/2024
18:30
500 - Gap the stock!

Could be tomorrow AM. Everything crossed for all genuine gamblers.

socionomics
16/9/2024
20:02
It isn't even the year, let alone the week.
supernumerary
16/9/2024
19:32
It feels like this is the week. We are so close now.
socionomics
21/8/2024
18:49
+ 100 : I need shares.
socionomics
15/8/2024
11:16
It seems as Jane Austin wrote in Pride and Prejudice and paraphrasing:

"It is a truth universally acknowledged that anyone who makes a future share price (direction) prediction may be both right and wrong, but that they will only ever highlight one of those conditions."

Of course the algo driven trading knows where to put the price but for IMM this isn't at least for now much of a issue although it seems someone is keeping it in a range.

PS agree with Nobby in 38701.

colsmith
14/8/2024
11:44
Good banter guys. Let's keep this thread informative and humorous. Nobby versus Socio. Who will prove to be right and over what time frame. Will Nobby turn positive?Looking at the depth of the red next to the IMM part of my portfolio I'm rooting for Socio and wondering whether to double my holding at these levels in a reckless attempt to salvage something from this otherwise disastrous investment (to date".
husbod
Chat Pages: 1568  1567  1566  1565  1564  1563  1562  1561  1560  1559  1558  1557  Older

Your Recent History

Delayed Upgrade Clock